Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | Exciting updates in R/R multiple myeloma: highlights at ASH 2022

Dan Vogl • 12 Dec 2022
ASH 2022
Multiple Myeloma Antibodies BiTEs CAR-T Cevostamab Mezigdomide Talquetamab

Dan Vogl, University of Pennsylvania, Philadelphia, PA, discusses exciting updates in the treatment of relapsed/refractory multiple myeloma (R/R MM) presented at ASH 2022, highlighting the promise of bispecific T-cell engagers (BiTEs), GPRC5D-directed CAR-T therapy, and novel agents, including mezigdomide. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Dan Vogl

3:09
First-in-human study of modakafusp alfa for the treatment of R/R multiple myeloma
Dan Vogl • 12 Dec 2022
3:50
Selinexor: a clear role in heavily pre-treated multiple myeloma
Dan Vogl • 17 May 2022
2:38
Modakafusp alfa combinations for treating multiple myeloma in the near future
Dan Vogl • 17 May 2022
2:45
Modakafusp alfa: promising results as a first-in-class immunocytokine for R/R multiple myeloma
Dan Vogl • 17 May 2022

Related Videos

4:24
Investigating production failure and out-of-specification production of CAR T-cell therapeutics
Nina Worel • 25 Apr 2024
1:14
Using MRD to accelerate drug approval in multiple myeloma
Karthik Ramasamy • 28 Apr 2024
3:54
Cilta-cel as a potential new SoC for R/R multiple myeloma: insights from the CARTITUDE-4 trial
Roberto Mina • 23 Apr 2024
1:41
CRS and neurotoxicity in bispecific antibody and CAR-T therapy for multiple myeloma
Eden Biltibo • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals